Patients with relapsed/refractory advanced/metastatic ovarian cancer (aOC), metastatic colorectal cancer (mCRC), metastatic pancreatic cancer (mPC), or cutaneous metastatic melanoma (MM) who have exhausted all treatment options.

• A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokin … Pending
  2025-521164-36-00 7

Showing 1–1 of 1 trials